Moderna's COVID-19 vaccine aces trial in teens, teeing up back-to-school FDA approval Mexico ramping up COVID-19 trial work tapping Sanofi, China's shots in late-stage tests A 'springboard' to the future: Genentech, Sanofi and Alnylam execs sound off on pharma's evolving back-to-work plans Physicians say COVID-19 has lowered their trust in organizational leadership and healthcare at large New House, Senate bills aim to make telehealth expansion permanent in Medicare, Medicaid Apeiron plans COVID-19 trial of inhaled ACE2 formulation Bristol Myers taps Xencor's half-life tech for COVID-19 antibody COVID-19 tracker: Half of adult Americans fully vaccinated; Bharat Biotech seeks WHO approval for Covaxin UPDATED Coronavirus tracker: HRSA to give nearly $5B to fund COVID-19 tests for uninsured Pharmacy giant CVS Health launches new clinical trial services biz, eyes siteless trials platform Curebase nabs $15M for siteless trials that revolve 'around the patient's lifestyle' Featured Story | By Eric Sagonowsky Teens across the U.S. started getting COVID-19 vaccines this month after Pfizer’s shot nabbed an emergency authorization in the age group. Moderna’s shot could soon be available to kids, too, thanks to new data released Tuesday. read more |
| |
|---|
|
Top Stories By Ben Adams French Big Pharma Sanofi, using its traditional vaccine approach, and Chinese biotech Walvax, using mRNA technology, are both set to start phase 3 trials in Mexico. read more By Fraiser Kansteiner,Noah Higgins-Dunn,Eric Sagonowsky Top pharma HR executives know that bringing the work-from-home crowd back to the office is a chance to completely rethink how and where people do their jobs. In interviews, execs from three drugmakers—Sanofi, Alnylam and Genentech—explained how their companies are doing just that. read more By Dave Muoio A recent poll of physicians and the general public found lower trust across the U.S. health system but steady or increased faith in the individuals who are providing care. read more By Robert King New legislation introduced recently in the House and Senate aims to make permanent flexibilities that caused a boom in telehealth use in response to the COVID-19 pandemic. read more By Nick Paul Taylor Apeiron Biologics is preparing to study an inhaled formulation of its ACE2 receptor decoy APN01. The clinical trial will test whether switching from intravenous to inhaled delivery can expand the patient population for the COVID-19 candidate. read more By Amirah Al Idrus Bristol Myers Squibb was a late entrant to the COVID-19 therapeutics space, picking up a pair of antibody treatments from Rockefeller University in February this year. Now, as the combination makes its way through phase 1 trials, the Big Pharma is licensing technology from Xencor that extends the treatment’s half-life. read more By Noah Higgins-Dunn,Kevin Dunleavy,Fraiser Kansteiner Half of all adult Americans are now fully vaccinated against COVID-19, and at least 61% have been given at least one dose, the Biden administration said. Bharat Biotech filed an emergency use application for its vaccine, known as Covaxin, with the World Health Organization. And more headlines. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Ben Adams CVS Health has navigated a pandemic that decimated footfall into its pharmacies but boosted demand for diagnostics and also saw it help pharma companies and CROs find trial subjects for COVID-19 tests. read more By Ben Adams Curebase has raised a $15 million series A for a new approach to decentralized trials that goes beyond the current drop of virtual trial platforms. read more |
